Type 1 Diabetes
Compared to standard insulin treatment, noninsulin antidiabetic agents did not present an increased risk for fetal losses or major malformations when used in the first trimester of pregnancy.
For patients with type 1 diabetes, artificial pancreas treatment is efficacious, increasing the proportion of time spent in the near normoglycemic range.
Physically active young adults with type 1 diabetes have alterations in mitochondrial ultrastructure and bioenergetics within skeletal muscle.
Awareness of ASD and its manifestations and comorbidities remain imperative in the treatment of T1D, as both conditions require long-term medical follow-up to continue improving diabetes care and metabolic control outcomes.
The type of sciatic nerve lesions observed in patients with diabetic peripheral neuropathy was found to differ in type 1 and type 2 diabetes.
Telemedicine could provide real-time feedback loop and allow pharmacists to help patients self-manage.
For adults with type 1 diabetes with suboptimal control despite using multiple insulin injections, continuous glucose monitoring seems cost-effective, with improved glucose control.
Young adults with type 1 diabetes have altered neural responses during working memory processing.
Researchers conducted a systematic literature review to identify studies on cognitive function in children with type 1 diabetes.
IPITA and EPITA held a workshop to develop consensus for a joint statement on the definition of function and failure of current and future forms of β-cell replacement therapy.
Anti-osteoporotic medications (mainly bisphosphonates) seem to equally prevent bone loss, especially in the lumbar spine, in patients with diabetes compared with patients without diabetes.
Early treatment of cardiovascular disease risk factors such as dyslipidemia and hypertension will have long-term benefits with low risk and cost and should be more widely used in pediatric type 1 diabetes care.
There are significant improvements in health-related quality of life following islet transplantation in patients with type 1 diabetes complicated by severe hypoglycemia.
Researchers assessed the safety and accuracy of an implantable continuous glucose measurement in adults diagnosed with type 1 and type 2 diabetes.
Study provided evidence of significant differences in median serum concentrations of circulating adipose-related inflammatory biomarkers across the main diabetes types.
The FDA reviewed data for the device through the de novo premarket review pathway, a regulatory pathway for novel, low-to-moderate-risk devices that are not substantially equivalent to an already legally marketed device.
Sanofi announced that the Food and Drug Administration (FDA) has approved Toujeo (insulin glargine 300 Units/mL) Max SoloStar, a long-acting insulin pen that holds 900 Units of Toujeo and provides up to 160 Units/mL per injection.
Researchers assessed whether alcohol intake affects response to glucagon in individuals with type 1 diabetes.
The NDA is based on results from a large placebo-controlled, phase 3 trial that included 1402 patients with type 1 diabetes who were receiving insulin therapy.
Researchers assessed differences in glycemic control, major cardiovascular risk factors, diabetes-related complications, sexual dysfunction prevalence, and endothelial function in young men and women with type 1 diabetes.
For pregnant women with type 1 diabetes, a closed-loop system is associated with comparable glucose control and significantly less hypoglycemia than sensor-augmented pump therapy.
Research findings indicate improved glycemic outcomes in children with T1D using the MiniMed 670G system, similar to those observed for adolescents and adults.
Researchers assessed racial and ethnic differences in outcomes among patients in the first 3 years following diagnosis of type 1 diabetes.
Study found that the absence of proliferative diabetic retinopathy in those with stage 3b chronic kidney disease is associated with a lower prevalence of cardiovascular disease in patients with long duration of type 1 diabetes.
Study suggests that single-hormone artificial pancreas systems may be sufficient for overnight control even in a high-risk group of hypoglycemia-unaware participants with documented nocturnal hypoglycemia.
High-quality studies are needed to determine whether tight intrapartum glycemic control is superior to more relaxed glycemic targets intrapartum for women with diabetes in pregnancy.
Researchers calculated the hazard ratio of ADHD in offspring of patients with type 1 diabetes compared with the general population.
Study showed gender-discordant metabolic impairment during puberty that was correlated with peak growth velocity in boys, but not in girls.
For youth with type 1 diabetes, disordered eating behaviors are associated with higher hemoglobin A1c but not with measures of glycemic variability.
Higher rates of operative delivery and falling gestational age at delivery suggest that this is either reflected by, or despite, increasing obstetric intervention.
Endocrinology Advisor Articles
- Obesity Risk in Infants Born to Women With Diabetes
- Nivolumab Associated With Thyroiditis in Patients With Cancer
- Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers
- Autism Does Not Affect Metabolic Control in Type 1 Diabetes
- Diabetes May Decrease Ability to Feel Acid Regurgitation
- Risk for Fetal Loss Early in Pregnancy Not Greater With Noninsulin vs Insulin Therapy
- ACP: Position Paper Recommends Solutions to Close Gender Equity Gap
- Vitamin D Insufficiency Associated With Insulin Resistance Independent of Obesity in Children
- Factors Identified to Predict Fatty Liver in Obese Teens
- Artificial Pancreas Treatment Efficacious for Type 1 Diabetes